Save the Cord Foundation and BioInformant Join Forces in Global Effort to Increase Cord Blood Banking Awareness

PRESS RELEASE; April 1, 2015
ST. PAUL, MN, and WASHINGTON, DC, and TUCSON, AZ

Press release available at PR Web:  http://www.prweb.com/releases/2015/04/prweb12627399.htm.

For expectant parents, there are thousands of decisions to make in a short amount of time, including clothes, cribs, names, birthing methods, medical procedures, and more. It can be overwhelming, especially given the short-time frame involved. In addition to these decisions, there is an often overlooked decision: what to do with the extremely valuable stem and progenitor cells contained within the umbilical cord of the expected newborn? There are three options, which are to publicly donate, to privately store, or to discard the umbilical cord as medical waste. Two of those decisions require research and action on behalf of the parents, while the third is what happens when sufficient awareness and education has not been provided to allow parents to make an informed, educated decision. Continue reading Save the Cord Foundation and BioInformant Join Forces in Global Effort to Increase Cord Blood Banking Awareness

WideCells – Stem Cell Biotechnology and Regenerative Medicine in the 21st Century

WideCells is a new and innovative stem cell technology and regenerative medicine company. It was founded by the CEO João Andrade and the CFO Lopes Gil. Dr Peter Hollands later joined as CSO bringing experience from other UK and international stem cell banks, clinical transplantation, teaching and research.

The first operations for WideCells were in Portugal, following on to the acquisition of the Spanish company Nacersalud to begin operations in Spain.

The continued success of operations in Portugal and Spain have led to the development of Continue reading WideCells – Stem Cell Biotechnology and Regenerative Medicine in the 21st Century

The 8 Best Stem Cell Quotes of 2015

Stem Cells are Transforming the Future of Medicine

Stem cells are ushering in an age of regenerative medicine.

They are all over the news, because they will transform the next 50 years of medicine in ways that are now inconceivable.

In coming decades, stem cells will be reversing diseases ranging from Alzheimer’s to autism, re-growing organs and tissues, and potentially allowing the first humans to reach the age of 200.

Already in 2015, here are three “science fictions” that have become “science facts”… Continue reading The 8 Best Stem Cell Quotes of 2015

BioInformant Releases “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report”

Overview Summary

Recent months have seen the first iPSC clinical trial in humans, creation of the world’s largest iPSC biobank, major funding awards, a historic challenge to the “Yamanaka Patent”, a Supreme Court ruling affecting industry patent rights, announcement of an iPSC cellular therapy clinic scheduled to open in 2019, and much more. Furthermore, iPSC patent dominance continues to cluster in specific geographic regions, while clinical trial and scientific publication trends give clear indicators of what may happen in the industry in 2015 and beyond.

Is it worth it to you to get informed about rapidly-evolving market conditions and identify key industry trends that will give you an advantage over your competition?

Report Applications

This global strategic report is produced for:

  • Management of Stem Cell Product Companies
  • Management of Stem Cell Therapy Companies
  • Stem Cell Industry Investors

Continue reading BioInformant Releases “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report”

Induced Pluripotent Stem Cells: Competitive Analysis of the U.S. Patent Landscape

Role of Patent Analysis for Competitive Intelligence

In 2006, groundbreaking experimentation led to the discovery of induced pluripotent stem cells (iPSCs), which are adult cells that are transformed into embryonic-like stem cells through the manipulation of gene expression or other related methods.  In 2007, follow-up experiments proved human adult cells could be transformed into iPSC cells.  Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells.

Today, the number of iPSC products sold worldwide is increasing with double-digit growth, and 22% of all stem cell researchers self-report having used iPSCs within a research project. It is clear that iPSCs represent a lucrative product market, but  commercializing the cell type involves careful and due diligence, because the cells are still a relatively new discovery.

Because the iPSC industry is a rapidly-evolving area, major research findings and technical discoveries are frequently announced . Therefore, to launch iPSC products and technologies, one of the key areas that company management and investors must consider is the patent landscape for the cell type.

Induced Pluripotent Stem Cell (iPSC) Patent Landscape

The United States federal government supports a searchable patent database, the “United State Patent and Trademark Office (USPTO) Full-Text and Image Database.”[2] It is a flexible and essential tool for analyzing the patent landscape  of any stem cell type.

When assessing a specific cell type, such as induced pluripotent stem cells, the USPTO patent database provides crucial information for several business intelligence (BI) metrics of importance, including: Continue reading Induced Pluripotent Stem Cells: Competitive Analysis of the U.S. Patent Landscape

If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]

Hematopoietic Stem Cells Transplant Rates, Utilization of Cord Blood, Awareness Rates, and More

The cord blood banking market has emerged gradually over the past 40 years, as 1974 was the first year in which it was proposed that stem and progenitor cells were present in human cord blood.[1]  In the forthcoming years it was established that cord blood stem cells had similar properties as bone marrow and could be used as an alternative.  Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell based therapy, both for the treatment of hematological and non-hematological disorders.
Continue reading If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]

Marvelous Stem Cell Video by Harvard School of Medicine (3 Minutes)

Best Video of 2015:  “Birth and Engraftment of Blood Stem Cell”

This video published by the Harvard School of Medicine is incredible! We’ve passed it around and have awarded it the “Stem Cell Video of the Year” award.

It’s a zebrafish animation that shows the discoveries made by the Stem Cell Research Program at Boston Children’s Hospital.  Using the zebrafish as a model, it takes you from the birth of a blood stem cell, along its travel through the body, to its site of engraftment.

The importance of these findings is that they reveal the natural process of blood stem cell activity, the first time this activity has been documented within a living system, as discussed on the Harvard School of Medicine site here. Continue reading Marvelous Stem Cell Video by Harvard School of Medicine (3 Minutes)

Cord Blood Scientific Publications May Predict What Will Happen in 2015 and Beyond

Trend rate data is valuable for understanding current industry conditions, as well as for predicting future behavior within the cord blood industry.

In upcoming posts, we will be presenting a range of valuable trend rate data, pulled from diverse sources, including grant funding databases, patent databases, clinical trial databases, and more.

In this post, we will begin with an analysis of scientific publication rate data for cord blood industry, because it is an important way to gauge innovation and progress within the marketplace.

Scientific Publication Rate Analysis

PubMed is a service of the U.S. National Library of Medicine and the National Institutes of Health (NIH) that contains citations from MEDLINE and a diverse collection of other life science journals. The data below was generated using the PubMed database, because it is the largest, most comprehensive, and most up-to-date global meta-database available for scientific publications.[1]

It is also the most versatile tool for screening by multiple criteria.

For purposes of this analysis, the search term “Cord Blood” was used. It was chosen because it captures all longer-tail searches, including words like: “Umbilical Cord Blood,” “Cord Blood Banking,” “Cord Blood Transplant,” and more.

To compare growth rates for the related service of cord tissue storage, the search term “Cord Tissue” was also examined. Again, this phrase captures all longer-tail searches, including phrases such as: “Cord Tissue Stem Cells,” “Cord Tissue Banking,” and more. See data below.

TABLE. TREND RATE ANALYSIS FOR “CORD BLOOD” & “CORD TISSUE” SCIENTIFIC PUBLICATIONS, BY YEAR

Cord Blood Scientitic Trend Rate Analysis (Table)

* Note: For the “% Year-Over-Year Change” column, years with a positive change are in green
and years with a negative change as in red.
The 2014 figures are full-year estimates based on PubMed data for January 1 – November 1, 2014.

Trend Rate Analysis

In the first graph below, you can see rates of scientific publications containing the term “Cord Blood” over a trailing 10-year period. The key finding is that a relatively predictable, linear increase in publications is observable over this period of time.

Analysis of Scientific Publications Containing "Cord Blood"Next, fitting an exponential best-fit line to this data set (Rvalue of­­­­­ 0.9863[2]) , five-year projection data predicts that cord blood publications will reach nearly 1,600 per year by 2019. Note that an exponential best-fit line better describes this data set than a linear, logarithmic, power, polynomial, or moving average best-fit line.

See five-year future projection data below.

5 Year Projection Analysis of Scientific Publications Containing Cord Blood

In the next graph, the same trailing 10-year historical analysis is completed for scientific publications containing the term “Cord Tissue.”

Analysis of Scientific Publications Containing Cord Tissue

Unfortunately, a best-fit line does not fit well for this “Cord Tissue” data set. Indeed, an exponential best-fit line, which is more accurate than a linear, logarithmic, power, polynomial, or moving average best-fit line for this data set, provides only an Rvalue of­­­­­ 0.7307.[3]

If one chooses to ignore the poor fit of this trend line and extrapolate for purposes of creating five-year projection data, then it predicts that cord tissue publications will reach approximately 125 per year by 2019. However, actual numbers could vary substantially from this prediction, given the described limitation of this best-fit line and the smaller quantities involved within this data set.

See five-year future projection data below.

5 Year Projection Analysis of Scientific Publications Containing Cord Tissue

Summary

In summary, there have been consistent linear increases in scientific publications containing the term “Cord Blood” for the past 10 years. While past behavior is not a guarantee of future behavior, this consistent trend suggests that accurate future predictions may be possible.

However, there have been less consistent trends observable for scientific publications containing the term “Cord Tissue.” As such, it is much more difficult to make accurate predictions in this area of stem cell medicine.

Future Posts about Cord Blood

To receive future posts cord blood, sign-up below. We will never share your information with anyone, and you can opt-out at any time.

 

Footnotes:                      

[1] Ncbi.nlm.nih.gov, (2014). Home – PubMed – NCBI. [online] Available at: http://www.ncbi.nlm.nih.gov/pubmed [Accessed 6 Nov. 2014].

[2]R² is a statistical term describing how good one term is at predicting another. If R² is 1.0 then given the value of one term, you can perfectly predict the value of another term. . If R² is 0.0, then knowing one term does not help you know the other term at all.

[3] Ibid.

About Us

BioInformant is the only research firm that has served the cord blood sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on prominent news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM).

cropped-BioInformant-Logo-As-Featured-On.jpg

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in cord blood industry data.

To learn more about emerging trends and opportunities within the cord blood banking industry, view the “Complete 2015-16 Global Cord Blood Banking Industry Report” now.

Complete 2015-16 Global Cord Blood Banking Industry Report

 

Business of Commercializing Induced Pluripotent Stem Cells [Infographic]

As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.

To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.

Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.
Continue reading Business of Commercializing Induced Pluripotent Stem Cells [Infographic]

Cord Blood Banking Industry: Key Benchmarks to Track (and Why You Should Care)

Recently released, the “Complete 2015-16 Global Cord Blood Banking Industry Report” reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the global cord blood market has matured substantially over the past few years, creating both serious threats and novel opportunities.

Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.
Continue reading Cord Blood Banking Industry: Key Benchmarks to Track (and Why You Should Care)

Data is boring. Put your trust in a new-age market research firm.

“Data is boring. Put your trust in a new-age market research firm. We’re young (under 40 team), innovative, and trained in applying bioinformatics – the science of analyzing complex biological data – to the field of market research.

With 4 zettabytes of data in the world, we’ll get rid of the noise and give you just the data you need to make more revenue.”

- Phone conversation with client; 9:03am EST today.  Learn more at: http://www.bioinformant.com/company/

 

BREAKING NEWS: Fujifilm Holdings Acquires Stem Cell Industry Leader Cellular Dynamics International (CDI)

Breaking News Just Released within the Induced Pluripotent Stem Cell (iPSC) Sector

TOKYO and MADISON, Wis., March 30, 2015 

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay) (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

Fujifilm aims to acquire all issued and outstanding shares of CDI’s common stock for $16.5 per share or approximately $ 307 million (on a fully diluted basis). The offer represents a premium of 108% to CDI’s closing price on March 27. Upon completion of the transaction, CDI will continue to run its operations in Madison, Wisconsin and Novato, California as a consolidated subsidiary of Fujifilm. Continue reading BREAKING NEWS: Fujifilm Holdings Acquires Stem Cell Industry Leader Cellular Dynamics International (CDI)

Need Results for Your Stem Cell Company or Cord Blood Bank? BioInformant Shares Testimonials

Competing in the Stem Cell Marketplace is a Difficult Task

For executives operating a stem cell company or cord blood bank, competing in the marketplace is a difficult task.  You must analyze market conditions, predict industry trends, and capitalize on market changes before the competition. Especially within the rapidly evolving stem cell marketplace, it can be difficult to make educated, informed decisions that produce revenue growth for your company, while limiting failed products that won’t have demand in the marketplace. Continue reading Need Results for Your Stem Cell Company or Cord Blood Bank? BioInformant Shares Testimonials

MarketResearch.com: “Blockbuster” Year for Stem Cells Creates Market Opportunities, Says BioInformant Report

PRESS RELEASE

WASHINGTON and NEW YORK CITY and LONDON, April 1, 2015 /PRNewswire/ – As a leading provider of market research reports and solutions, MarketResearch.com is pleased to highlight a report by BioInformant Worldwide, LLC, indicating that 2015 will be a year of market growth and opportunity for the stem cell industry.

For executives operating a stem cell company or cord blood bank, competing in the stem cell marketplace is a difficult task. You must analyze market conditions, predict industry trends, and act on market changes before the competition. Especially within the rapidly evolving stem cell marketplace, it can be difficult to make educated, informed decisions that produce revenue growth, while limiting failed products.

BioInformant specializes exclusively in stem cell market research and is the only research firm that has been tracking the market since it emerged.  Because there are hematopoietic stem cells in cord blood and mesenchymal stem cells in cord tissue, BioInformant has also been tracking the cord blood industry since 2006. One of BioInformant’s most popular global strategic reports is the “Complete 2015-16 Global Cord Blood Banking Industry Report.”

Published to assist company leaders and cord blood industry investors, this global cord blood report is designed to increase efficiency and effectiveness in:

  1. Communicating effectively with existing and potential clients
  2. Launching high-demand products and services
  3. Increasing revenue
  4. Taking market share from your competition
  5. Commercializing cord blood products, technologies, and therapies
  6. Making intelligent investment decisions

The global cord blood market has matured substantially over the past few years, creating both novel opportunities and serious threats.  Serious threats to the industry include new accreditation requirements that have increased the cost structure of cord blood banks, a recent decline in cord blood transplants, low rates of turnover for stored cord blood units, difficulty with educating obstetricians about cellular therapies, and more. Marketing pressures are also impacting the industry, with the term “cord blood” becoming one of the 20 most expensive search terms on Google, reaching more than $20 per click for global search traffic and close to $40 per click for U.S. search traffic.

Additionally, awareness rates are limiting market potential. A study published in the Journal of Reproductive Medicine identified that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” A recent “Parent Survey” conducted by BioInformant Worldwide, LLC that incorporated 600+ responses from recent and expectant parents identified that awareness percentages have shifted little since the prior study was published.

However, there are also substantial opportunities for company executives who are positioned to take advantage of them, including the potential to expand the cord blood market through increased awareness, new clinical trial data supporting applications for hematopoietic stem cells (HSCs), improving public perception toward stem cell therapies, substantial deal-making within the industry, an industry trend toward diversified bio-banking, and much more.

Within the rapidly evolving stem cell marketplace, individuals who commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage. Some stem cell companies and cord blood banks will make expensive new hires or a maintain business developments in an effort to compete, but you don’t need to. For a much smaller investment, you can immediately make informed, educated decisions about your marketplace.

Click here to view all reports by BioInformant.

BioInformant’s stem cell market research is also available on www.profound.com, where subscribers are able to purchase only the individual sections, chapters, tables or charts of a report they need without having to pay for the pieces they don’t.

About MarketResearch.com
MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world’s most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com’s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance.

Connect with us on LinkedIn https://www.linkedin.com/company/marketresearch
Follow us on Facebook http://www.facebook.com/marketresearchdotcom
Follow us on Twitter http://www.twitter.com/marketresearch_

About BioInformant Worldwide
BioInformant specializes in global strategic reports for the stem cell industry and is the only research firm that has served the stem cell sector since it emerged. BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, and more. In addition, BioInformant’s management team comes from a “bioinformatics” background, the science of collecting and analyzing complex genetic codes. We are trained in applying these data analysis techniques to the field of market research. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your trusted source of stem cell industry data.

MarketResearch.com
240.747.3008
press@marketresearch.com

Cord Blood Scholarly Research Round-Up [March 2015]

The cord blood banking market is rapidly evolving. Major research advances are announced every month. Innovation is the only constant.

Under these circumstances, it is difficult to tracking the ever-changing landscape of the cord blood banking market. Therefore, these scholarly research round-ups highlight “must know” research advances occurring in the sector, both those published by extremely well-regarded researchers (such as Joanne Kurtzberg’s article below), as well as those published by up-and-coming scientists.  Continue reading Cord Blood Scholarly Research Round-Up [March 2015]